Osmotic diuretic

An osmotic diuretic is a type of diuretic that inhibits reabsorption of water and sodium (Na). They are pharmacologically inert substances that are given intravenously. They increase the osmolarity of blood and renal filtrate.[1] This fluid eventually becomes urine.

Two examples are mannitol[2] and isosorbide.

In the nephron, osmotic diuretics act at the portions of the nephron that are water-permeable.[3]

Osmotic diuretics work by expanding extracellular fluid and plasma volume, therefore increasing blood flow to the kidney. This washes out the cortical medullary gradient in the kidney. This stops the loop of Henle from concentrating urine, which usually uses the high osmotic and solute gradient to transport solutes and water.

These agents can also act at other parts of the body. For example, they can be used to reduce intracranial[4] and intra-ocular pressure. Osmotic diuretics increase plasma volume, but because they do not cross the blood-brain barrier, this does not affect the nervous system. In effect, this is the cause of their action reducing locally the plasma volume in the nervous system.

## Mechanism of action

[edit]

Osmotic diuretics have their major effect in the proximal convoluted tubule and the descending limb of the Loop of Henle. These sites are freely permeable to water. Through osmotic effects, they also oppose the action of ADH in the collecting tubule. The presence of a nonreabsorbable solute such as mannitol prevents the normal absorption of water by interposing a countervailing osmotic force. As a result, urine volume increases.

The increase in urine flow rate decreases the contact time between fluid and the tubular epithelium, thus reducing sodium as well as water reabsorption. The resulting natriuresis is of lesser magnitude than the water diuresis, leading eventually to excessive water loss and hypernatremia.

Any osmotically active agent that is filtered by the glomerulus but not reabsorbed causes water to be retained in these segments and promotes a water diuresis. Such agents can be used to reduce intracranial pressure and to promote prompt removal of renal toxins. The prototypical osmotic diuretic is mannitol.[5]

Mannitol lowers the intra cranial pressure through two effects in the brain. The first, rheological effect, reduces blood viscosity, and promotes plasma expansion and cerebral oxygen delivery. In response, cerebral vasoconstriction occurs due to autoregulation, and cerebral blood volume is decreased. The second effect occurs through creation of an osmotic gradient across the blood-brain barrier, leading to the movement of water from the parenchyma to the intravascular space. Brain tissue volume is decreased and, therefore, ICP is lowered.[6][7]

## See also

[edit]

* Osmosis

## References

[edit]

1. ^ "osmotic diuretic" at Dorland's Medical Dictionary
2. ^ "Mannitol". Retrieved 2008-12-20.
3. ^ Trevor, Anthony J.; Katzung, Bertram G. (2003). Pharmacology. New York: Lange Medical Books/McGraw-Hill, Medical Publishing Division. p. 46\. ISBN 0-07-139930-5.
4. ^ Sakowitz OW, Stover JF, Sarrafzadeh AS, Unterberg AW, Kiening KL (February 2007). "Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients". J Trauma. 62 (2): 292–8. doi:10.1097/01.ta.0000203560.03937.2d. PMID 17297315.
5. ^ Brunton, Laurence (2011). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (12th ed.). The McGraw-Hill Companies, Inc. pp. Chapter 25.
6. ^ Messeter, Kenneth; Nordström, Carl-Henrik; Sundbärg, Göran; Algotsson, Lars; Ryding, Erik (February 1986). "Cerebral hemodynamics in patients with acute severe head trauma". Journal of Neurosurgery. 64 (2): 231–237. doi:10.3171/jns.1986.64.2.0231. ISSN 0022-3085. PMID 3080555.
7. ^ James, H. E. (September 1980). "Methodology for the control of intracranial pressure with hypertonic mannitol". Acta Neurochirurgica. 51 (3–4): 161–172. doi:10.1007/bf01406742. ISSN 0001-6268. PMID 6768226. S2CID 40808775.

## External links

[edit]

* Media related to Osmotic diuretics at Wikimedia Commons

* v
* t
* e

Diuretics (C03)

Sulfonamides
(and etacrynic acid)|

| CA inhibitors (at PT)|

* Acetazolamide

|

Loop (Na-K-Cl at AL)|

* Furosemide#
* Azosemide
* Bumetanide
* Etacrynic acid
* Etozolin
* Indacrinone
* Muzolimine
* Ozolinone
* Piretanide
* Tienilic acid‡
* Torasemide

Thiazides (Na-Cl at DCT,
Calcium-sparing)|

* Altizide
* Bendroflumethiazide
* Butizide
* Chlorothiazide
* Cyclopenthiazide
* Cyclothiazide
* Epitizide
* Hydrochlorothiazide
* Hydroflumethiazide
* Mebutizide
* Methyclothiazide
* Polythiazide
* Trichlormethiazide

Thiazide-likes (primarily DCT)|

* Chlortalidone
* Clofenamide
* Clopamide
* Clorexolone
* Fenquizone
* Indapamide
* Mefruside
* Meticrane
* Metolazone
* Quinethazone
* Xipamide

Potassium-sparing (at CD)|

| ESC blockers|

* Amiloride#
* Benzamil
* Triamterene

|

Aldosterone antagonists|

* Spirolactones
* Spironolactone#
* Canrenone
* Eplerenone
* Potassium canrenoate

* Nonsteroidal
* Finerenone

Osmotic diuretics (PT, DL)|

* Mannitol#
* Glycerol
* Urea

Vasopressin receptor inhibitors
(DCT and CD)|

* Vaptans
* Conivaptan
* Mozavaptan
* Satavaptan
* Tolvaptan

* Others
* Demeclocycline
* Lithium carbonate

Other|

* Ethanol, Isopropanol, 2M2B
* mercurial diuretics (Chlormerodrin, Mersalyl, Meralluride)
* Theobromine
* Cicletanine

Combination products|

* Hydrochlorothiazide/triamterene

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template